Dynavax drops request for EU approval of Hepatitis B vaccine

|About: Dynavax Technologies Corp... (DVAX)|By:, SA News Editor

Dynavax (DVAX +1.7%) withdraws its application for the European approval of the company's Hepatitis B vaccine Heplisav after the European Medicines Agency (EMA) indicated that the product's safety database is too small to rule out the risk of less common serious side-effects.

Dynavax plans to soon start another Heplisav trial in order to provide a large enough database. (PR)